Physician profile
Nathan Easterlin
NPI 1144373051
$1,123.59
in general payments reported to CMS, 2019-2025
14 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $94.93 · 2021: $81.92 · 2022: $179 · 2023: $110 · 2024: $192 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $178.89 | 2019-2020 | |
| Organogenesis INC. | $158.34 | 2020-2024 | Puraply |
| Kerecis Limited | $147.92 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Smith+Nephew, INC. | $146.73 | 2019-2025 | Collagenase Santyl |
| Regeneron Healthcare Solutions, INC. | $143.20 | 2022-2025 | Libtayo |
| Abbvie INC. | $120.06 | 2023-2025 | |
| Musculoskeletal Transplant Foundation INC. | $64.87 | 2022 | |
| Tela Bio, INC. | $56.20 | 2021-2022 | |
| Kci USA, INC. | $30.26 | 2019 | |
| Avita Medical Americas, LLC | $21.90 | 2024 | |
| Davol INC. | $19.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.63 | 2022 | |
| Apyx Medical Corporation | $11.90 | 2020 | |
| Medela LLC | $9.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Easterlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.